Editas Medicine (LTS:0IFK) Ending Cash Position : $135.42 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Editas Medicine Ending Cash Position?

Editas Medicine's Ending Cash Position for the quarter that ended in Dec. 2024 was $135.42 Mil.

Editas Medicine's quarterly Ending Cash Position increased from Jun. 2024 ($68.32 Mil) to Sep. 2024 ($99.71 Mil) and increased from Sep. 2024 ($99.71 Mil) to Dec. 2024 ($135.42 Mil).

Editas Medicine's annual Ending Cash Position declined from Dec. 2022 ($145.40 Mil) to Dec. 2023 ($127.53 Mil) but then increased from Dec. 2023 ($127.53 Mil) to Dec. 2024 ($135.42 Mil).

Editas Medicine Ending Cash Position Historical Data

The historical data trend for Editas Medicine's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine Ending Cash Position Chart

Editas Medicine Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

143.56

207.40

145.40

127.53

135.42

Editas Medicine Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															127.53	73.10	68.32	99.71	135.42

Editas Medicine Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Editas Medicine's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	127.529	+	7.889
	=	135.42

Editas Medicine's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	99.709	+	35.709
	=	135.42

Editas Medicine Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Editas Medicine's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Editas Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (LTS:0IFK) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

EDIT:USA 8EM:Germany

Address

11 Hurley Street, Cambridge, MA, USA, 02141

Website

https://www.editasmedicine.com

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Editas Medicine Headlines

No Headlines